文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-DOTATATE PRRT患者及临床仿真中减少时间点成像对时间积分活度影响的准确性与不确定性分析

Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for 177Lu-DOTATATE PRRT in patients and clinically realistic simulations.
PubMed 文献 · EJNMMI Res · 2023-06-12

本研究纳入28例胃肠胰神经内分泌肿瘤患者,利用第一周期177Lu-DOTATATE治疗后约4、24、96、168小时的SPECT/CT数据,分析减少时间点方法估算时间积分活度(TIA)的误差与变异性,并以仿真验证。结果显示减少时间点方法在多种采样方案下可获得可接受的TIA平均误差并保持低不确定性。

要点

  • 单时间点估算TIA的最佳显像时间为治疗后3-5天(71-126小时),脾脏采用一种单时间点方法例外为6-8天(144-194小时)。
  • 最佳时间点下单时间点估算各结构平均百分比误差在±5%以内、标准差<9%,肾脏TIA误差最大(MPE=-4.1%)、变异性最高(SD=8.4%)。
  • 两时间点最佳采样为治疗后1-2天(21-52小时)加3-5天(71-126小时),三时间点为1-2天加3-5天加6-8天(144-194小时)。

核心结论

  • 减少时间点方法可在较宽的显像时间点和采样方案范围内获得可接受的平均TIA误差并保持低不确定性,有助于提高177Lu-DOTATATE剂量学的可行性并阐明非理想条件下的不确定性。

研究设计与样本

  • 研究纳入28例胃肠胰神经内分泌肿瘤患者,在第一周期177Lu-DOTATATE治疗后约4、24、96、168小时行SPECT/CT显像。
  • 勾画健康肝脏、左右肾脏、脾脏及最多5个指标肿瘤,依据赤池信息准则以单指数或双指数函数拟合时间-活度曲线。
  • 以全部4个时间点拟合为参考,比较2个和3个时间点的各种组合以确定最佳显像方案及相关误差,并评估2种常用的单时间点TIA估算方法。
  • 仿真研究从临床数据衍生的对数正态分布中采样曲线拟合参数并加入真实测量噪声生成数据,评估不同采样方案的TIA误差与变异性。

主要发现

  • 单时间点估算TIA的最佳显像时间为治疗后3-5天(71-126小时),适用于肿瘤和器官,但脾脏采用一种单时间点方法例外为6-8天(144-194小时)。
  • 最佳时间点下单时间点估算各结构MPE在±5%以内、SD<9%,肾脏TIA误差最大(MPE=-4.1%)、变异性最高(SD=8.4%)。
  • 两时间点估算TIA的最佳采样为治疗后1-2天(21-52小时)加3-5天(71-126小时),适用于肾脏、肿瘤和脾脏;该方案下脾脏MPE绝对值最大为1.2%,肿瘤变异性最高(SD=5.8%)。
  • 三时间点估算TIA的最佳采样为治疗后1-2天(21-52小时)加3-5天(71-126小时)加6-8天(144-194小时),适用于所有结构;该方案下脾脏MPE绝对值最大为2.5%,肿瘤变异性最高(SD=2.1%)。
  • 仿真患者结果与临床结果一致,呈现相似的的最佳采样方案和误差;许多次优的减少时间点采样方案也表现出低误差和低变异性。

关键数值与推荐

  • 单时间点估算TIA的最佳显像时间:肿瘤和器官为治疗后3-5天(71-126小时),脾脏采用一种单时间点方法为6-8天(144-194小时)。
  • 两时间点估算TIA的最佳采样:治疗后1-2天(21-52小时)加3-5天(71-126小时),适用于肾脏、肿瘤和脾脏。
  • 三时间点估算TIA的最佳采样:治疗后1-2天(21-52小时)加3-5天(71-126小时)加6-8天(144-194小时),适用于所有结构。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dosimetry promises many advantages for radiopharmaceutical therapies but repeat post-therapy imaging for dosimetry can burden both patients and clinics. Recent applications of reduced time point imaging for time-integrated activity (TIA) determination for internal dosimetry following 177Lu-DOTATATE peptide receptor radionuclide therapy have shown promising results that allow for the simplification of patient-specific dosimetry. However, factors such as scheduling can lead to sub-optimal imaging time points, but the resulting impact on dosimetry accuracy is still under investigation. We use four-time point 177Lu SPECT/CT data for a cohort of patients treated at our clinic to perform a comprehensive analysis of the error and variability in time-integrated activity when reduced time point methods with various combinations of sampling points are employed. METHODS: The study includes 28 patients with gastroenteropancreatic neuroendocrine tumors who underwent post-therapy SPECT/CT imaging at approximately 4, 24, 96, and 168 h post-therapy (p.t.) following the first cycle of 177Lu-DOTATATE. The healthy liver, left/right kidney, spleen and up to 5 index tumors were delineated for each patient. Time-activity curves were fit with either monoexponential or biexponential functions for each structure, based on the Akaike information criterion. This fitting was performed using all 4 time points as a reference and various combinations of 2 and 3 time points to determine optimal imaging schedules and associated errors. 2 commonly used methods of single time point (STP) TIA estimation are also evaluated. A simulation study was also performed with data generated by sampling curve fit parameters from log-normal distributions derived from the clinical data and adding realistic measurement noise to sampled activities. For both clinical and simulation studies, error and variability in TIA estimates were estimated with various sampling schedules. RESULTS: The optimal post-therapy imaging time period for STP estimates of TIA was found to be 3-5 days (71-126 h) p.t. for tumor and organs, with one exception of 6-8 days (144-194 h) p.t. for spleen with one STP approach. At the optimal time point, STP estimates give mean percent errors (MPE) within ± 5% and SD < 9% across all structures with largest magnitude error for kidney TIA (MPE = - 4.1%) and highest variability also for kidney TIA (SD = 8.4%). The optimal sampling schedule for 2TP estimates of TIA is 1-2 days (21-52 h) p.t. followed by 3-5 days (71-126 h) p.t. for kidney, tumor, and spleen. Using the optimal sampling schedule, the largest magnitude MPE for 2TP estimates is 1.2% for spleen and highest variability is in tumor with SD = 5.8%. The optimal sampling schedule for 3TP estimates of TIA is 1-2 days (21-52 h) p.t. followed by 3-5 days (71-126 h) p.t. and 6-8 days (144-194 h) p.t. for all structures. Using the optimal sampling schedule, the largest magnitude MPE for 3TP estimates is 2.5% for spleen and highest variability is in tumor with SD = 2.1%. Simulated patient results corroborate these findings with similar optimal sampling schedules and errors. Many sub-optimal reduced time point sampling schedules also exhibit low error and variability. CONCLUSIONS: We show that reduced time point methods can be used to achieve acceptable average TIA errors over a wide range of imaging time points and sampling schedules while maintaining low uncertainty. This information can improve the feasibility of dosimetry for 177Lu-DOTATATE and elucidate the uncertainty associated with non-ideal conditions.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Peterson AB, Mirando DM, Dewaraja YK, et al. Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for 177Lu-DOTATATE PRRT in patients and clinically realistic simulations. EJNMMI Res. 2023. PMID: 37306783. doi:10.1186/s13550-023-01007-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。